<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Real-world evidence on migraine treatment in routine clinical practice: insights from the Türkiye migraine registry study using artificial intelligence algorithms

dc.contributor.authorDikmen, Pinar Yalinay
dc.contributor.authorAydinlar, Elif Ilgaz
dc.contributor.authorDumlu, Seda N.
dc.contributor.authorOnal, Tugay
dc.contributor.authorGumru, Salih
dc.contributor.authorOnganer, Efe
dc.contributor.authorLoleyt, Alex
dc.date.accessioned2026-11-05T11:00:36Z
dc.date.issued2026
dc.description.abstractBackground Despite available diagnostic and therapeutic options, a major unmet need persists in migraine care. This study applied artificial intelligence (AI) to extract structured insights from routine care and assess migraine burden, diagnosis, and treatment in T & uuml;rkiye.Methods The T & uuml;rkiye Migraine Registry Study was a retrospective, observational study across 23 hospitals and clinics in eight cities. Anonymized electronic health records (EHRs) of 11,023 adults treated between January 2021 and October 2023 were analyzed. A validated AI framework with natural language processing and machine learning extracted demographics, comorbidities, imaging, and prescriptions. Descriptive statistics summarized outcomes.Results Of 90,381 neurology patients, 16,751 (18.5%) had migraine or suspected migraine; 11,023 met inclusion. Only 46.9% carried an ICD-10 migraine code, while 53.1% were coded under other headache syndromes yet frequently received migraine-specific therapies. The cohort was 73% female, mean age 41.5. Neuroimaging was frequent (58.7% MRI, 15.2% CT), and 18.4% visited emergency care. Preventive therapy was prescribed to 63.7%, mainly antidepressants (31.4%) and beta-blockers (19.4%). OnabotulinumtoxinA and CGRP monoclonal antibodies were used in 10.3 and 3.4%.Conclusion AI-assisted EHR analysis revealed underdiagnosis, high imaging use, and limited adoption of mechanism-specific preventives in T & uuml;rkiye, underscoring the need for improved diagnostic accuracy and broader access to modern therapies.
dc.description.pages1848551
dc.description.sponsorshipThe author(s) declared that financial support was received for this work and/or its publication. This study was funded by Pfizer Pharmaceuticals Turkey. Data analysis of Ac & imath;badem Health Group records was conducted by Transverse Health, contracted by Pfizer Pharmaceuticals Turkey. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
dc.description.volume17
dc.identifier.doi10.3389/fneur.2026.1848551
dc.identifier.issn1664-2295
dc.identifier.urihttps://doi.org/10.3389/fneur.2026.1848551
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10493
dc.identifier.wosWOS:001862552500001
dc.language.isoen
dc.publisherFRONTIERS MEDIA SA
dc.relation.fundingPfizer Pharmaceuticals Turkey
dc.relation.hasversion10.3389/fneur.2026.1848551
dc.relation.ispartofFRONTIERS IN NEUROLOGY
dc.subjectartificial intelligence
dc.subjectelectronic health records
dc.subjectmigraine
dc.subjectnatural language processing
dc.subjectreal-world evidence
dc.subjectT & uuml
dc.subjectrkiye
dc.subjectHEADACHE
dc.subjectSEX
dc.subjectClinical Neurology
dc.subjectNeurosciences
dc.subjectNeurosciences & Neurology
dc.titleReal-world evidence on migraine treatment in routine clinical practice: insights from the Türkiye migraine registry study using artificial intelligence algorithms
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.volume17
person.identifier.ridD-2590-2015
person.identifier.ridJQW-2566-2023

Files

Collections